ArticleFrontiers in medicine2026
Targeting neutrophil extracellular traps: an emerging strategy for improving the management of refractory asthma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-refractory asthma, particularly the neutrophilic-predominant phenotype, poses a significant clinical challenge. Current therapies, especially corticosteroids, have limited efficacy in controlling inflammation in these patients, highlighting the need for novel targets against non-eosinophilic inflammation. This review examines the central role of neutrophil extracellular traps (NETs) in driving persistent airway inflammation, tissue damage, and remodeling in refractory asthma. It also evaluates preclinical and translational evidence for therapeutic strategies targeting NETs-such as inhibiting their formation, promoting degradation, neutralizing toxic components, and enhancing clearance. Despite challenges in target specificity, patient heterogeneity, and delivery, integrating these strategies with precision medicine could open new disease-modifying avenues to improve outcomes in treatment-refractory asthma, especially the neutrophilic phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.